A Study to Compare Pharmacokinetics of GB1211
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Galecto Biotech AB
- Target Recruit Count
- 13
- Registration Number
- NCT05747573
- Locations
- 🇳🇱
QPS Netherlands BV, Groningen, Netherlands
A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).
- Conditions
- Interventions
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Galecto Biotech AB
- Target Recruit Count
- 88
- Registration Number
- NCT05240131
- Locations
- 🇫🇷
CHRU, Tours, France
🇵🇱Samodzielny Publiczny Zespol Gruzlicy I Chorob Pluc, Olsztyn, Poland
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
A Single and Repeat Dose Trial in Participants With Hepatic Impairment
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- Galecto Biotech AB
- Target Recruit Count
- 54
- Registration Number
- NCT05009680
- Locations
- 🇧🇬
University Multiprofile Hospital, Clinic of gastroenterology, Sofia, Оborishte District, Bulgaria
🇧🇬COAMC Medical, Sofia, Bulgaria
🇧🇬Gastroenterology Clinic, Lozenets district, Sofia, Bulgaria
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Galecto Biotech AB
- Target Recruit Count
- 21
- Registration Number
- NCT04679870
- Locations
- 🇺🇸
MD Andersson Cancer Hospital, Houston, Texas, United States
🇦🇺Woden Dermatology, Canberra, Australia
🇩🇪Universität Leipzig, Leipzig, Germany
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Galecto Biotech AB
- Registration Number
- NCT04607655
A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2019-02-06
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Galecto Biotech AB
- Target Recruit Count
- 172
- Registration Number
- NCT03832946
- Locations
- 🇺🇸
Harvard Medical School - Brigham and Womens Hospital (BWH), Boston, Massachusetts, United States
🇺🇸University of Texas Health Sciences Center at Houston, Houston, Texas, United States
🇺🇸University of Texas Health Centre at Houston, Houston, Texas, United States
A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- Galecto Biotech AB
- Target Recruit Count
- 78
- Registration Number
- NCT03809052
- Locations
- 🇬🇧
(For Parts A and B) Covance Clinical Research Unit Ltd, Leeds, United Kingdom
RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients
- Conditions
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Galecto Biotech AB
- Target Recruit Count
- 60
- Registration Number
- NCT02257177
- Locations
- 🇬🇧
Royal Devon & Exeter Foundation NHS Trust, Exeter, Devon, United Kingdom
🇬🇧Edinburgh University Hospital, Edinburgh, Scotland, United Kingdom
🇬🇧The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, Tyne And Wear, United Kingdom